AstraZeneca stock gains on Deutsche Bank upgrade

Published on 09/21/2026 at 10:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca stock rose after Deutsche Bank lifted its view to hold on September 15, 2026. The shares closed at 12,500.0 pence on September 18, 2026.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor — AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

AstraZeneca stock (ISIN GB0009895292) closed at 12,500.0 pence on September 18, 2026, up 72.0 pence or 0.58 percent on the day, while Deutsche Bank moved its rating to hold and raised its target to 11,700 pence on September 15, 2026. The move came after the bank cited last week's negative SERENA-4 readout and a period of underperformance versus European large-cap peers, according to Sharecast.

Price and broker reset

In London trading, the stock moved within a 12,398.0 pence to 12,596.0 pence range on September 18, 2026, with volume of 6.52 million shares, and MarketBeat said on September 19, 2026 that the 52-week range runs from GBP 107.84 to GBP 157.32. That leaves AstraZeneca about 20.5 percent below the yearly high and gives the shares a market value of about GBP 193.86 billion as of September 19, 2026.

MarketBeat also said AstraZeneca had fallen 9.4 percent year to date from GBP 137.90 at the start of 2026 to GBP 125.00, and it listed a consensus target of USD 206.67 with a Moderate Buy rating on September 20, 2026. For investors, the split between the new Deutsche Bank hold call and the wider consensus target is the key tension.

Latest reported figures

MarketBeat said AstraZeneca's last quarterly earnings release came on July 27, 2026, when the company reported EPS of USD 2.63, ahead of the USD 2.50 consensus by USD 0.13. It also said revenue rose 6.4 percent year on year, giving the stock a fresh fundamental anchor beyond the recent broker move.

On the same page, MarketBeat put AstraZeneca's trailing P/E at 24.83 and its dividend yield at 2.61 percent. That combination matters because the share price has already moved back to 12,500.0 pence while the last reported profit and sales figures still point to a business with earnings support.

Stock stays below high

AstraZeneca stock finished at 12,500.0 pence on September 18, 2026, and the 52-week high of GBP 157.32 remains the chart level to watch. The London listing remains the reference price for the shares.